Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Specialty Generics Market, by Type
1.4.2 North America Specialty Generics Market, by Application
1.4.3 North America Specialty Generics Market, by End Use
1.4.4 North America Specialty Generics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Product Launches and Product Expansions: 2020, May – 2023, Jan) Leading Players
Chapter 4. North America Specialty Generics Market by Type
4.1 North America Injectables Market by Country
4.2 North America Oral Drugs Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Specialty Generics Market by Application
5.1 North America Inflammatory conditions Market by Country
5.2 North America Multiple sclerosis Market by Country
5.3 North America Hepatitis C Market by Country
5.4 North America Oncology Market by Country
5.5 North America Others Market by Country
Chapter 6. North America Specialty Generics Market by End Use
6.1 North America Specialty Pharmacy Market by Country
6.2 North America Retail Pharmacy Market by Country
6.3 North America Hospital Pharmacy Market by Country
Chapter 7. North America Specialty Generics Market by Country
7.1 US Specialty Generics Market
7.1.1 US Specialty Generics Market by Type
7.1.2 US Specialty Generics Market by Application
7.1.3 US Specialty Generics Market by End Use
7.2 Canada Specialty Generics Market
7.2.1 Canada Specialty Generics Market by Type
7.2.2 Canada Specialty Generics Market by Application
7.2.3 Canada Specialty Generics Market by End Use
7.3 Mexico Specialty Generics Market
7.3.1 Mexico Specialty Generics Market by Type
7.3.2 Mexico Specialty Generics Market by Application
7.3.3 Mexico Specialty Generics Market by End Use
7.4 Rest of North America Specialty Generics Market
7.4.1 Rest of North America Specialty Generics Market by Type
7.4.2 Rest of North America Specialty Generics Market by Application
7.4.3 Rest of North America Specialty Generics Market by End Use
Chapter 8. Company Profiles
8.1 Teva Pharmaceutical Industries Ltd.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Product Launches and Product Expansions:
8.2 Novartis AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.3 Hikma Pharmaceuticals PLC
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Product Launches and Product Expansions:
8.4 Sun Pharmaceutical Industries Ltd.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Product Launches and Product Expansions:
8.5 Fresenius SE & Co. KGaA
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Acquisition and Mergers:
8.6 Dr. Reddy’s Laboratories Ltd.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Product Launches and Product Expansions:
8.7 Mallinckrodt PLC
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.8 Bausch Health Companies, Inc
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.9 Viatris, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.10. Apotex, Inc.
8.10.1 Company Overview
Unique Offerings 